128 related articles for article (PubMed ID: 36315463)
1. Real-life clinical impact of a five-tiered classification of pituitary tumors.
Sahakian N; Appay R; Resseguier N; Graillon T; Piazzola C; Laure C; Figarella-Branger D; Régis J; Castinetti F; Brue T; Dufour H; Cuny T
Eur J Endocrinol; 2022 Dec; 187(6):893-904. PubMed ID: 36315463
[TBL] [Abstract][Full Text] [Related]
2. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification.
Raverot G; Dantony E; Beauvy J; Vasiljevic A; Mikolasek S; Borson-Chazot F; Jouanneau E; Roy P; Trouillas J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3368-3374. PubMed ID: 28651368
[TBL] [Abstract][Full Text] [Related]
3. Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients.
Lelotte J; Mourin A; Fomekong E; Michotte A; Raftopoulos C; Maiter D
Eur J Endocrinol; 2018 Mar; 178(3):237-246. PubMed ID: 29259039
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of a clinicopathological classification in predicting treatment-related outcomes and multimodal therapeutic approaches in pituitary adenoma patients: retrospective analysis on a Portuguese cohort of 129 patients from a tertiary pituitary center.
Peixe C; Alexandre MI; Gomes AR; Nobre E; Silva AL; Oliveira T; López-Presa D; Faria CC; Miguens J; Bugalho MJ; Marques P
Pituitary; 2023 Aug; 26(4):352-363. PubMed ID: 37072661
[TBL] [Abstract][Full Text] [Related]
5. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.
Trouillas J; Roy P; Sturm N; Dantony E; Cortet-Rudelli C; Viennet G; Bonneville JF; Assaker R; Auger C; Brue T; Cornelius A; Dufour H; Jouanneau E; François P; Galland F; Mougel F; Chapuis F; Villeneuve L; Maurage CA; Figarella-Branger D; Raverot G; ; Barlier A; Bernier M; Bonnet F; Borson-Chazot F; Brassier G; Caulet-Maugendre S; Chabre O; Chanson P; Cottier JF; Delemer B; Delgrange E; Di Tommaso L; Eimer S; Gaillard S; Jan M; Girard JJ; Lapras V; Loiseau H; Passagia JG; Patey M; Penfornis A; Poirier JY; Perrin G; Tabarin A
Acta Neuropathol; 2013 Jul; 126(1):123-35. PubMed ID: 23400299
[TBL] [Abstract][Full Text] [Related]
6. MRI and Trouillas' grading system of pituitary tumors: the usefulness of T2 signal intensity volumetric values.
Calandrelli R; Pilato F; D'Apolito G; Schiavetto S; Gessi M; D'Alessandris QG; Lauretti L; Gaudino S
Neuroradiology; 2023 Nov; 65(11):1567-1578. PubMed ID: 37233819
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.
Lv L; Yin S; Zhou P; Hu Y; Chen C; Ma W; Jiang Y; Wang Z; Jiang S
World Neurosurg; 2018 Oct; 118():e428-e435. PubMed ID: 29981466
[TBL] [Abstract][Full Text] [Related]
8. A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s.
Guaraldi F; Zoli M; Righi A; Gibertoni D; Marino Picciola V; Faustini-Fustini M; Morandi L; Bacci A; Pasquini E; Mazzatenta D; Asioli S
Clin Endocrinol (Oxf); 2020 Jul; 93(1):36-43. PubMed ID: 32306401
[TBL] [Abstract][Full Text] [Related]
9. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre.
Asioli S; Righi A; Iommi M; Baldovini C; Ambrosi F; Guaraldi F; Zoli M; Mazzatenta D; Faustini-Fustini M; Rucci P; Giannini C; Foschini MP
Eur J Endocrinol; 2019 Feb; 180(2):127-134. PubMed ID: 30481158
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Related Factors of Tumor Recurrence or Progression After Transnasal Sphenoidal Surgical Treatment of Large and Giant Pituitary Adenomas and Establish a Nomogram to Predict Tumor Prognosis.
Chen Y; Cai F; Cao J; Gao F; Lv Y; Tang Y; Zhang A; Yan W; Wang Y; Hu X; Chen S; Dong X; Zhang J; Wu Q
Front Endocrinol (Lausanne); 2021; 12():793337. PubMed ID: 34970226
[TBL] [Abstract][Full Text] [Related]
11. Predictors of pituitary tumour behaviour: an analysis from long-term follow-up in 2 tertiary centres.
Lenders NF; Earls PE; Wilkinson AC; Costin M; Hofer M; Shein TT; Harvey RJ; Krishnan G; Picallo M; Pal A; Wass J; McCormack AI
Eur J Endocrinol; 2023 Jul; 189(1):106-114. PubMed ID: 37461224
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
13. World Health Organization Grade II Meningiomas: The Role of Adjuvant/Salvage Gamma Knife Surgery After Initial Surgery and Prognostic Factor Assessment.
Liu X; Shan B; Wang M; Xu J
World Neurosurg; 2018 Jan; 109():e352-e362. PubMed ID: 28987849
[TBL] [Abstract][Full Text] [Related]
14. Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Dekkers O; Popovic V; Wierinckx A; McCormack A; Petersenn S; Burman P; Raverot G; Villa C
Rev Endocr Metab Disord; 2020 Jun; 21(2):243-251. PubMed ID: 32504268
[TBL] [Abstract][Full Text] [Related]
15. Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach.
Calandrelli R; Mattogno PP; Chiloiro S; Gessi M; D'Apolito G; Tartaglione T; Giampietro A; Bianchi A; Doglietto F; Lauretti L; Gaudino S
Diagnostics (Basel); 2024 Jan; 14(3):. PubMed ID: 38337790
[TBL] [Abstract][Full Text] [Related]
16. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up.
Zakir JC; Casulari LA; Rosa JW; Rosa JW; de Mello PA; de Magalhães AV; Naves LA
Int J Endocrinol; 2016; 2016():7964523. PubMed ID: 27635138
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.
Nishiyama N; Kitamura H; Maeda T; Takahashi S; Masumori N; Hasegawa T; Tsukamoto T
Jpn J Clin Oncol; 2013 Nov; 43(11):1124-31. PubMed ID: 23980236
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
